Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy

Journal of Digestive Diseases

Volumn 13, Issue 4, 2012, Pages 219-224

  Han, Xiao Feng ^a   Wang, Qi Xia ^a   Liu, Yuan ^a   You, Zheng Rui ^a   Bian, Zhao Lian ^a   Qiu, De Kai ^a   Ma, Xiong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Alkaline phosphatase; Combination therapy; Fenofibrate; Fibrate; Primary biliary cirrhosis; Ursodeoxycholic acid

Indexed keywords

ALKALINE PHOSPHATASE; CHOLESTEROL; FENOFIBRATE; GAMMA GLUTAMYLTRANSFERASE; TRIACYLGLYCEROL; URSODEOXYCHOLIC ACID;

ADD ON THERAPY; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL TISSUE; ARTICLE; CHINESE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; MALE; NONHUMAN; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PRURITUS; RAT; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; CHOLAGOGUES AND CHOLERETICS; DRUG THERAPY, COMBINATION; FEMALE; FENOFIBRATE; HUMANS; HYPOLIPIDEMIC AGENTS; LIVER CIRRHOSIS, BILIARY; MALE; MIDDLE AGED; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 84863347646     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2012.00574.x     Document Type: Article

References (18)

1. Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol 2010; 52: 745-58.
2. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005; 353: 1261-73.
3. Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006; 101: 1529-38.
4. Parés A, Caballeria L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130: 715-20.
5. Corpechot C, Abenavoli L, Rabahi N etal. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008; 48: 871-7.
6. Miyaguchi S, Ebinuma H, Imaeda H etal. A novel treatment for refractory primary biliary cirrhosis? Hepatogastroenterology 2000; 47: 1518-21.
7. Iwasaki S, Ohira H, Nishiguchi S etal. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatol Res 2008; 38: 557-64.
8. Kanda T, Yokosuka O, Imazeki F, Saisho H. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol 2003; 38: 573-8.
9. Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol 2004; 10: 894-8.
10. Liberopoulos EN, Florentin M, Elisaf MS, Mikhailidis DP, Tsianos E. Fenofibrate in primary biliary cirrhosis: a pilot study. Open Cardiovasc Med J 2010; 4: 120-6.
11. Ohira H, Sato Y, Ueno T, Sata M. Fenofibrate treatment in patients with primary biliary cirrhosis. Am J Gastroenterol 2002; 97: 2147-9.
12. Nakamuta M, Enjoji M, Kotoh K, Shimohashi N, Tanabe Y. Long-term fibrate treatment for PBC. J Gastroenterol 2005; 40: 546-7.
13. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology 2009; 50: 291-308.
14. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978; 379: 103-12.
15. Walker LJ, Newton J, Jones DE, Bassendine MF. Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2009; 49: 337-8; author reply 338.
16. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996; 384: 39-43.
17. Chianale J, Vollrath V, Wielandt AM etal. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Biochem J 1996; 314: 781-6.
18. Vree JM de, Jacquemin E, Sturm E etal. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci U S A 1998; 95: 282-7.